Thomas King | VP of Translational R&D
Sabin Vaccine Institute

Tom is an established leader in vaccine development with a 33-year background in biotechnology who has led R&D programs for several private and publicly traded companies. Across these roles he developed animal models to study the immunogenicity and efficacy of adenoviral, microbial, and subunit vaccines that were developed clinically against cancer and infectious disease targets.  These efforts led to > 20 FDA-regulated clinical trials and a recent BLA. His role at Sabin includes collaborative oversight of the ChAd3-based filovirus vaccines program with a focus on NHP studies, assay development, and CMC. Tom earned his Ph.D. in 2001 at the University of Massachusetts, Amherst and is an inventor/author of >50 patents and peer-reviewed publications. He is eager to leverage his experience to reduce suffering and expand access to more efficacious and affordable vaccines.